What is VRXA's health score?

Veraxa Biotech Holding AG (VRXA) has a TradeApes health score of N/A out of 100, rated N/A. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is VRXA's estimated fair value?

Based on our 5-year discounted cash flow model, Veraxa Biotech Holding AG's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is VRXA undervalued or overvalued?

Our model currently rates VRXA as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Get live scores & alerts on your phone

📱 Get the App

Create an account for unlimited access

Crunching the numbers for VRXA... Refresh in a moment for the full analysis.

Veraxa Biotech Holding AG (VRXA)

Healthcare Inconclusive inconclusive

$2.05

Updated: 2026-07-17

—

TradeApes Score

Financial Strength

—

Operating Trend

—

Relative Value

—

Capital Allocation

—

Risk Management

—

Key Findings

Analysis is being generated. Refresh shortly to see key findings.

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.